FDx Advisors Inc. Has $450,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

FDx Advisors Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,365 shares of the biopharmaceutical company’s stock after buying an additional 117 shares during the quarter. FDx Advisors Inc.’s holdings in Gilead Sciences were worth $450,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new position in Gilead Sciences during the 1st quarter worth approximately $462,000. Quantbot Technologies LP acquired a new position in shares of Gilead Sciences in the first quarter valued at approximately $573,000. ProShare Advisors LLC increased its position in shares of Gilead Sciences by 21.7% during the first quarter. ProShare Advisors LLC now owns 1,480,987 shares of the biopharmaceutical company’s stock worth $108,482,000 after acquiring an additional 263,645 shares in the last quarter. Neumann Capital Management LLC raised its holdings in shares of Gilead Sciences by 2.0% during the first quarter. Neumann Capital Management LLC now owns 40,990 shares of the biopharmaceutical company’s stock worth $3,003,000 after acquiring an additional 800 shares during the period. Finally, Motley Fool Asset Management LLC lifted its position in Gilead Sciences by 351.1% in the 1st quarter. Motley Fool Asset Management LLC now owns 169,220 shares of the biopharmaceutical company’s stock valued at $12,395,000 after acquiring an additional 131,711 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,437 shares of company stock worth $5,374,825. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Piper Sandler increased their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday. Eleven analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.50.

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $1.82 during mid-day trading on Monday, hitting $98.39. 1,892,765 shares of the stock were exchanged, compared to its average volume of 7,025,229. The firm’s 50-day simple moving average is $85.30 and its 200 day simple moving average is $75.15. The stock has a market capitalization of $122.49 billion, a price-to-earnings ratio of 1,073.00, a price-to-earnings-growth ratio of 3.36 and a beta of 0.17. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.11.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The company’s revenue was up 7.0% on a year-over-year basis. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.13%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.